| Autor: |
MIYAZAKI, KUNIHIKO, SHIOZAWA, TOSHIHIRO, OKAUCHI, SHINICHIRO, SAKURAI, HIROFUMI, SATOH, HIROAKI, HIZAWA, NOBUYUKI |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Cancer Diagn Progn |
| ISSN: |
2732-7787 |
| DOI: |
10.21873/cdp.10204 |
| Popis: |
Background/Aim: The antineoplastic drug docetaxel (DOC) and the antivascular endothelial growth factor inhibitor ramucirumab (RAM) are widely used in combination for second or later-line regimens for advanced non-small cell lung cancer (NSCLC). While the median progression-free survival (PFS) of DOC+RAM has been reported to be less than six months in both clinical trials and clinical practice, there appear to be some patients with long-term PFS. This study aimed to clarify the existence and characteristics of these patients. Patients and Methods: We conducted a retrospective review of patients with advanced NSCLC treated with DOC+RAM between April 2009 and June 2022 at our three hospitals. There was no established definition of long-term PFS, thus in this study, a PFS of 12 months or longer was defined as long-term PFS. Results: During the study period, 91 patients received DOC+RAM treatment. Of these, 14 (15.4%) achieved long-term PFS. There were no significant differences in patient characteristics between patients with PFS ≥12 months and those with PFS |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
